Exhibit 99.1 

ITAMAR MEDICAL REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS

- Second Quarter Revenues Increase 21% to $8.9 Million -

- U.S. WatchPAT^TM Revenues Increase 31% to $6.6 Million -

- Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT -

CAESAREA, Israel, August 11, 2020-- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today reported unaudited financial results for the second quarter of 2020.

“Our second quarter results reflect encouraging growth and we have taken several steps to capitalize on this momentum. The recent traction among both new and existing customers in the context of survey results from 300 centers indicating volumes of 70% Home Sleep Apnea Tests versus volumes of 30% in-lab¹ is a testament to the advantage of our home-based and digital care pathway sleep solutions and our ability to reach the large undiagnosed patient population suffering from sleep apnea,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical.

“While we are pleased with our solid results, there are still many macro factors that remain fluid as the pandemic unfolds, leading to our cautious near-term outlook as we approach the second half of the year. Nonetheless, this does not change our long-term value proposition or market opportunity,” concluded Glick.

Second Quarter 2020 Highlights

· Revenues in the second quarter of 2020 were $8.9 million, an increase of 21% year-over-year.

· U.S WatchPAT revenues in the second quarter of 2020 were $6.6 million, an increase of 31% year-over-year.

Recent Business and Production Updates

· Doubled WatchPAT ONE production capacity from approximately 3,000 units per week in May to approximately 6,000 units per week in June to meet the overwhelming demand as seen in our backlog from the first quarter, which, as a result, is now normalized.

· Active centers using WatchPAT ONE reached a total of 291 after onboarding over 10 new customers per week on average throughout the second quarter.

¹ COVID-19 sleep center impact study. EnsoData. 2020. Available at https://www.ensodata.com/landing-pages/covid-19-sleep-center-impact-study.

Second Quarter 2020 Financial Results

Revenues for the second quarter of 2020 increased 21% to $8.9 million, compared to $7.4 million in the same quarter in 2019. Revenue growth was driven by an increase in WatchPAT sales in the U.S. and Japan, offset by a decrease in WatchPAT sales in Europe and in the rest of the world.

WatchPAT revenues for the second quarter of 2020 increased 20% to $7.9 million, compared to $6.5 million in the same quarter in 2019.

U.S. WatchPAT revenues for the second quarter of 2020 increased 31% to $6.6 million, compared to $5.0 million in the same quarter in 2019, driven primarily by WatchPAT ONE sales as well as WatchPAT Direct sales. Sales from disposables and renewable products, including WatchPAT ONE, comprised approximately 78% of WatchPAT revenues in the U.S. in the second quarter of 2020, compared to 65% in the same quarter in 2019.

Gross profit for the second quarter of 2020 increased to $6.0 million, compared to $5.7 million in the same quarter in 2019. Gross profit margin for the second quarter of 2020 decreased to 68%, compared to 78% in the same quarter in 2019. Non-IFRS gross profit margin for the second quarter of 2020 decreased to 70%, compared to 79% in the same quarter in 2019) See “Use of Non-IFRS Measures” below(. Gross margin decline was manly driven by the increase in WatchPAT ONE sales.

Operating loss for the second quarter of 2020 was $3.2 million, compared to $1.7 million in the same quarter in 2019. The increase in operating loss was primarily attributable to an increase in operating expenses, partially offset by the increase in revenues. Selling and marketing expenses increased 31% to $5.9 million, compared to $4.5 million in the same quarter in 2019, due to the planned expansion of the U.S. sales team into new geographical territories and verticals (32 territories and verticals as of June 30, 2020, compared to 27 territories and verticals as of June 30, 2019), as well as additional sales commissions resulting from the increase in revenues. Research and development expenses increased 22% to 1.4 million, compared to $1.1 million in the same quarter in 2019, driven by an increase in personnel to support product development (including the digital health platform).

Non-IFRS operating loss for the second quarter of 2020 was $2.4 million, compared to $0.9 million in the same quarter in 2019. Non-IFRS operating loss excludes approximately $0.8 million in share-based payments; depreciation and amortization of property and equipment and intangible assets; change in provision for doubtful and bad debt; and expenses relating to reduction in manpower, compared to $0.8 million of similar expenses for the same quarter in 2019 (see “Use of Non-IFRS Measures” below).

Net loss for the second quarter of 2020 was $3.2 million, compared to $2.0 million in the same quarter in 2019.

Non-IFRS net loss for the second quarter of 2020 was $2.4 million, compared to $1.2 million in the same quarter in 2019. Non-IFRS net loss excludes approximately $0.8 million in share-based payments; depreciation and amortization of property and equipment and intangible assets; change in provision for doubtful and bad debt; expenses relating to reduction in manpower; and gain from reevaluation of derivatives, compared to $0.7 million of similar expenses and gains for the same quarter in 2019 (see “Use of Non-IFRS Measures” below).

As of June 30, 20, the Company had cash, cash equivalents and a short-term bank deposit of $45.2 million.

First Half 2020 Financial Results

Revenues for the six months ended June 30, 2020 increased 29% to $17.3 million, compared to $13.4 million for the six months ended June 30, 2019. Revenue growth was driven by an increase in WatchPAT sales in the U.S. and Japan, offset by a decrease in WatchPAT sales in the rest of the world.

WatchPAT revenues for the six months ended June 30, 2020 increased 30% to $16.1 million, compared to $12.3 million for the six months ended June 30, 2019.

U.S. WatchPAT revenues for the six months ended June 30, 2020 increased 36% to $12.7 million, compared to $9.3 million for the six months ended June 30, 2019. U.S. WatchPAT revenues increase was primarily driven by the increase of WatchPAT ONE as well as WatchPAT Direct sales.

Gross profit for the six months ended June 30, 2020 increased to $12.3 million, compared to $10.4 million for the six months ended June 30, 2019. Gross profit margin for the for the six months ended June 30, 2020 was 72%, compared to 77% for the six months ended June 30, 2019. Non-IFRS gross profit margin for six months ended June 30, 2020 decreased to 73%, compared to 79% for the six months ended June 30, 2019 (See “Use of Non-IFRS Measures” below(. Gross margin decline was mainly driven by the increase in WatchPAT ONE sales.

Operating loss for the six months ended June 30, 2020 was $5.2 million, compared to $3.0 million for the six months ended June 30, 2019. The increase in operating loss was primarily attributable to an increase in operating expenses, partially offset by the increase in revenues. Selling and marketing expenses increased 36% to $11.2 million, compared to $8.3 million in the first half of 2019, due to the planned expansion of the U.S. sales team into new geographical territories and verticals, as well as additional sales commissions resulting from the increase in revenues. Research and development expenses increased 29% to $2.7 million, compared to $2.1 million in the first half of 2019, driven by an increase in personnel to support product development (including the digital health platform).

Non-IFRS operating loss for the six months ended June 30, 2020 was $3.8 million, compared to $1.9 million for the six months ended June 30, 2019. Non-IFRS operating loss excludes approximately $1.4 million in share-based payments; depreciation and amortization of property and equipment and intangible asset; change in provision for doubtful and bad debt; and expenses relating to reduction in manpower, compared to $1.1 million of similar expenses for the six months ended June 30, 2019 (see “Use of Non-IFRS Measures” below).

Net loss for the six months ended June 30, 2020 was $5.2 million, compared to $3.1 million for the six months ended June 30, 2019.

Non-IFRS net loss for the for the six months ended June 30, 2020 was $3.9 million, compared to $2.4 million for the six months ended June 30, 2019. Non-IFRS net loss excludes approximately $1.3 million in share-based payments; depreciation and amortization of property and equipment and intangible assets; change in provision for doubtful and bad debt; expenses relating to reduction in manpower; and gain from reevaluation of derivatives, compared to $0.7 million of similar expenses and gains for the six months ended June 30, 2019 (see “Use of Non-IFRS Measures” below).

Conference Call and Webcast Information

The Company will host a conference call today at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update.

To listen live via webcast, please visit https://www.itamar-medical.com/, or by clicking here.

To participate via phone, please use the dial in information:

U.S. toll-free: 833-519-1272
International: 914-800-3844
Israel toll-free: 1-809-315-362

Conference ID: 8798951

Please log in approximately 10 minutes prior to the scheduled start time. An archived webcast also will be provided in the Events and Presentations section of the Company’s website.

Use of Non-IFRS Measures

In addition to disclosing financial results prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB), this press release contains Non-IFRS financial measures for operating loss and net loss, which are adjusted from results based on IFRS to exclude: (i) share-based payments; (ii) depreciation and amortization of property and equipment and intangible assets; (iii) change in provision for doubtful and bad debt; (iv) expenses relating to reduction in manpower; and (v) gain from reevaluation of derivatives. Management believes that the Non-IFRS financial measures provided in this press release are useful to investors’ understanding and assessment of the Company’s performance. Management uses both IFRS and Non-IFRS measures when operating and evaluating the Company’s business internally and therefore decided to make these Non-IFRS adjustments available to investors. The presentation of this Non-IFRS financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. For further details, see a reconciliation of operating loss and net loss on an IFRS basis to a Non-IFRS basis that is provided in the table that accompanies this press release.

About Itamar Medical Ltd.

Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPAT, is commercially available within major markets including the U.S., Japan and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss the momentum gained by our business we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of Itamar Medical's control and actual results, expressed or implied by such forward-looking statements, could differ materially from Itamar Medical's current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by Itamar Medical in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC) and the Israel Securities Authority (ISA), including the Company’s latest Annual Report on Form 20-F, which is on file with the SEC (accessible at www.sec.gov) and the ISA. Except as otherwise required by law, Itamar Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Company Contact

Itamar Medical Ltd.

Shy Basson

Chief Financial Officer

Phone: +972-4-617-7700

bshy@itamar-medical.com

Itamar Medical Investor Relations Contact (U.S.)

Leigh Salvo or Caroline Paul

Gilmartin Group

Phone: +1-415-937-5412

investors@itamar-medical.com

* The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release.

ITAMAR MEDICAL LTD.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited)

	June 30, 2020			December 31, 2019
	U.S. dollars in thousands
Assets
Current assets
Cash and cash equivalents	$	37,666		$	15,115
Short-term bank deposit		7,500			-
Trade receivables		7,662			8,384
Other receivables		2,015			1,404
Inventories		4,727			3,363
Total current assets		59,570			28,266
Non-current assets
Long-term restricted deposits and prepaid expenses		519			476
Long-term trade receivables		263			156
Property and equipment		1,924			1,472
Intangible assets		687			395
Right-of-use assets		1,961			2,442
Total non-current assets		5,354			4,941
Total assets	$	64,924		$	33,207
Liabilities
Current liabilities
Short-term bank loan	$	5,000		$	5,000
Current maturities of lease liabilities		883			890
Trade payables		2,646			2,028
Other accounts payable		3,248			3,455
Accrued expenses		1,119			1,317
Provisions		334			273
Short-term employee benefits		593			352
Total current liabilities		13,823			13,315
Non-current liabilities
Lease liabilities, net of current maturities		1,253			1,708
Recognized liability for defined benefit plan, net		203			260
Other long-term liabilities		1,262			1,260
Total non-current liabilities		2,718			3,228
Total liabilities		16,541			16,543
Equity
Ordinary share capital		1,133			878
Additional paid-in capital		161,407			125,435
Accumulated deficit		(114,157	)		(109,649	)
Total equity		48,383			16,664
Total liabilities and equity	$	64,924		$	33,207

ITAMAR MEDICAL LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
	U.S. dollars in thousands (except per share and ADS data)
Revenues	$	8,885		$	7,353		$	17,263		$	13,409
Cost of revenues		2,869			1,627			4,919			3,029
Gross profit		6,016			5,726			12,344			10,380
Selling and marketing expenses		5,943			4,546			11,206			8,268
Research and development expenses		1,377			1,130			2,679			2,070
General and administrative expenses		1,914			1,793			3,634			3,080
Total operating expenses		9,234			7,469			17,519			13,418
Operating loss		(3,218	)		(1,743	)		(5,175	)		(3,038	)
Financial income (expenses):
Financial income		152			101			387			193
Financial expenses		(166	)		(298	)		(400	)		(596	)
Gain from derivatives instruments, net		-			78			-			442
Financial income (expenses), net		(14	)		(119	)		(13	)		39
Loss before taxes on income		(3,232	)		(1,862	)		(5,188	)		(2,999	)
Taxes on income		(10	)		(96	)		(52	)		(123	)
Net loss	$	(3,242	)	$	(1,958	)	$	(5,240	)	$	(3,122	)
Loss per share – basic and diluted (in U.S. dollars)	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.01	)
Weighted average number of shares used in computation of loss per shares (in thousands):
Basic		423,137			333,951			406,624			331,087
Diluted		423,137			335,149			406,624			331,087
Loss per ADS – basic and diluted (in U.S. dollars)	$	(0.23	)	$	(0.18	)	$	(0.39	)	$	(0.28	)
Weighted average number of ADSs used in computation of loss per ADS (in thousands):
Basic		14,105			11,132			13,554			11,036
Diluted		14,105			11,172			13,554			11,036

ITAMAR MEDICAL LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
	U.S. dollars in thousands
Cash flows from operating activities
Net loss	$	(3,242	)	$	(1,958	)	$	(5,240	)	$	(3,122	)
Adjustments for:
Depreciation and amortization		479			343			889			674
Share-based payment		309			355			671			531
Change in provision for doubtful and bad debt		126			207			158			194
Net financial cost (income)		(102	)		148			(199	)		172
Gain from reevaluation of derivatives		-			(78	)		-			(442	)
Decrease (increase) in trade receivables		(728	)		(251	)		456			(59	)
Increase in other accounts receivable		(832	)		(318	)		(604	)		(190	)
Increase in inventories		(1,054	)		(247	)		(1,815	)		(520	)
Increase in trade payables		151			147			580			525
Increase (decrease) in other accounts payable and accrued expenses		866			78			(426	)		314
Increase in employee benefits		166			39			245			129
Increase in provisions		10			3			61			7
Income tax expenses		10			96			52			123
Taxes paid during the period		(29	)		(17	)		(30	)		(44	)
Net interest received (paid) during the period		127			(166	)		53			(174	)
Net cash used in operating activities		(3,743	)		(1,619	)		(5,149	)		(1,882	)
Cash flows from investing activities
Investment in short-term bank deposits		(7,500	)		(9,000	)		(7,500	)		(9,000	)
Investment in restricted long-term deposits		(50	)		-			(50	)		-
Purchase of property and equipment, intangible assets and capitalization of development expenditure		(478	)		(116	)		(709	)		(262	)
Net cash used in investing activities		(8,028	)		(9,116	)		(8,259	)		(9,262	)
Cash flows from financing activities
Proceeds from issuance of shares, net of share issuance costs (share issuance costs)		(876	)		-			36,185			13,968
Repayment of principal of lease liabilities		(220	)		(215	)		(445	)		(439	)
Issuance of shares due to the exercise of stock options		81			14			81			25
Net cash provided by (used in) financing activities		(1,015	)		(201	)		35,821			13,554
Increase (decrease) in cash and cash equivalents		(12,786	)		(10,936	)		22,413			2,410
Cash and cash equivalents at beginning of period		50,442			19,887			15,115			6,471
Effect of exchange rate fluctuations on balances of cash and cash equivalents		10			65			138			135
Cash and cash equivalent balance at end of period	$	37,666		$	9,016		$	37,666		$	9,016
Non-cash financing activity- share issuance costs	$	38		$	-		$	38		$	-

ITAMAR MEDICAL LTD.

RECONCILIATIONS OF IFRS TO NON-IFRS FINANCIAL MEASURES

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
	U.S. dollars in thousands (except per share and ADS data)
IFRS operating loss	$	(3,218	)	$	(1,743	)	$	(5,175	)	$	(3,038	)
IFRS net loss	$	(3,242	)	$	(1,958	)	$	(5,240	)	$	(3,122	)
Cost of revenues:
Share-based payment		5			2			7			4
Depreciation and amortization of property and equipment and intangible assets		162			90			264			169
Expenses relating to reduction of manpower		27			-			27			-
		194			92			298			173
Operating expenses:
Selling and marketing:
Share-based payment		80			169			199			168
Depreciation and amortization of property and equipment and intangible assets		37			30			68			59
Expenses relating to reduction of manpower		63			-			63			-
		180			199			330			227
Research and development:
Share-based payment		71			25			142			54
Depreciation and amortization of property and equipment and intangible assets		31			16			50			28
Expenses relating to reduction of manpower		18			115			18			115
		120			156			210			197
General and administrative:
Share-based payment		147			153			310			293
Depreciation and amortization of property and equipment and intangible assets		18			14			34			26
Change in provision for doubtful and bad debt		126			207			158			194
Expenses relating to reduction of manpower		9			-			9			-
		300			374			511			513
Financial income (expenses), net:
Share-based payment		6			6			13			12
Gain from reevaluation of derivatives		-			(78	)		-			(442	)
		6			(72	)		13			(430	)
Non-IFRS operating loss	$	(2,424	)	$	(922	)	$	(3,826	)	$	(1,928	)
Non-IFRS net loss	$	(2,442	)	$	(1,209	)	$	(3,878	)	$	(2,442	)
IFRS loss per ADS – basic and diluted (in U.S. dollars)	$	(0.23	)	$	(0.18	)	$	(0.39	)	$	(0.28	)
Non-IFRS loss per ADS – basic and diluted (in U.S. dollars)	$	(0.17	)	$	(0.11	)	$	(0.29	)	$	(0.22	)